These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 37491519)
61. [Hemolytic uremic syndrome due to Shiga toxin–producing Escherichia coli and hypocomplementemia with favorable response to eculizumab: a case report]. Balestracci A; Meni Battaglia L; Martin SM; Toledo I; Puyol I; Beaudoin L; Robledo NL Rev Fac Cien Med Univ Nac Cordoba; 2021 Jun; 78(2):188-192. PubMed ID: 34181840 [TBL] [Abstract][Full Text] [Related]
62. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. Nitschke M; Sayk F; Härtel C; Roseland RT; Hauswaldt S; Steinhoff J; Fellermann K; Derad I; Wellhöner P; Büning J; Tiemer B; Katalinic A; Rupp J; Lehnert H; Solbach W; Knobloch JK JAMA; 2012 Mar; 307(10):1046-52. PubMed ID: 22416100 [TBL] [Abstract][Full Text] [Related]
63. Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing Bruyand M; Mariani-Kurkdjian P; Le Hello S; King LA; Van Cauteren D; Lefevre S; Gouali M; Jourdan-da Silva N; Mailles A; Donguy MP; Loukiadis E; Sergentet-Thevenot D; Loirat C; Bonacorsi S; Weill FX; De Valk H; Euro Surveill; 2019 Feb; 24(8):. PubMed ID: 30808442 [TBL] [Abstract][Full Text] [Related]
64. Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli infection in Argentina: update of serotypes and genotypes and their relationship with severity of the disease. Alconcher LF; Balestracci A; Coccia PA; Suarez ADC; Ramírez FB; Monteverde ML; Perez Y Gutiérrez MG; Carlopio PM; Principi I; Estrella P; Micelli S; Leroy DC; Quijada NE; Seminara C; Giordano MI; Hidalgo Solís SB; Saurit M; Caminitti A; Arias A; Liern M; Rivas M Pediatr Nephrol; 2021 Sep; 36(9):2811-2817. PubMed ID: 33604727 [TBL] [Abstract][Full Text] [Related]
65. A practical composite risk score for the development of Haemolytic Uraemic Syndrome from Shiga toxin-producing Escherichia coli. Hamilton D; Cullinan J Eur J Public Health; 2019 Oct; 29(5):861-868. PubMed ID: 31326985 [TBL] [Abstract][Full Text] [Related]
66. Comparative genomic analysis of a Shiga toxin-producing Escherichia coli (STEC) O145:H25 associated with a severe pediatric case of hemolytic uremic syndrome in Davidson County, Tennessee, US. Guerra JA; Zhang C; Bard JE; Yergeau D; Halasa N; Gómez-Duarte OG BMC Genomics; 2020 Aug; 21(1):564. PubMed ID: 32807093 [TBL] [Abstract][Full Text] [Related]
68. Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS). Loos S; Oh J; van de Loo L; Kemper MJ; Blohm M; Schild R Pediatr Nephrol; 2021 Nov; 36(11):3777-3783. PubMed ID: 34046736 [TBL] [Abstract][Full Text] [Related]
69. Haemolytic Uremic Syndrome: A Study Cohort over 10-Year Period in a Paediatric Tertiary Centre Hospital. Alletto A; Attaianese F; Montemaggi A; Becherucci F; Romagnani P; Trapani S Nephron; 2023; 147(6):337-350. PubMed ID: 36543152 [TBL] [Abstract][Full Text] [Related]
72. Interventions for Shiga toxin-producing Escherichia coli gastroenteritis and risk of hemolytic uremic syndrome: A population-based matched case control study. Myojin S; Pak K; Sako M; Kobayashi T; Takahashi T; Sunagawa T; Tsuboi N; Ishikura K; Kubota M; Kubota M; Igarashi T; Morioka I; Miyairi I PLoS One; 2022; 17(2):e0263349. PubMed ID: 35120154 [TBL] [Abstract][Full Text] [Related]
73. Gastrointestinal involvement in STEC-associated hemolytic uremic syndrome: 10 years in a pediatric center. Giordano M; Iacoviello O; Santangelo L; Martino M; Torres D; Carbone V; Scavia G; Loconsole D; Chironna M; Cristofori F; Francavilla R Pediatr Nephrol; 2024 Jun; 39(6):1885-1891. PubMed ID: 38189960 [TBL] [Abstract][Full Text] [Related]
74. Hemoglobinuria for the early identification of STEC-HUS in high-risk children: data from the ItalKid-HUS Network. Capone V; Mancuso MC; Tamburini G; Montini G; Ardissino G Eur J Pediatr; 2021 Sep; 180(9):2791-2795. PubMed ID: 33759020 [TBL] [Abstract][Full Text] [Related]
78. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Westra D; Volokhina EB; van der Molen RG; van der Velden TJ; Jeronimus-Klaasen A; Goertz J; Gracchi V; Dorresteijn EM; Bouts AH; Keijzer-Veen MG; van Wijk JA; Bakker JA; Roos A; van den Heuvel LP; van de Kar NC Pediatr Nephrol; 2017 Feb; 32(2):297-309. PubMed ID: 27718086 [TBL] [Abstract][Full Text] [Related]
79. Prognostic factors among patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: A retrospective cohort study using a nationwide inpatient database in Japan. Myojin S; Michihata N; Shoji K; Takanashi JI; Matsui H; Fushimi K; Miyairi I; Yasunaga H J Infect Chemother; 2023 Jun; 29(6):610-614. PubMed ID: 36871823 [TBL] [Abstract][Full Text] [Related]
80. CFH and CFB mutations in Shiga toxin-associated haemolytic uraemic syndrome in a 6-year-old boy. Çelakil ME; Yücel BB; Bek K Paediatr Int Child Health; 2020 May; 40(2):129-131. PubMed ID: 31242818 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]